PT  - JOURNAL ARTICLE
AU  - GOEDHALS, LOUIS
AU  - FALKSON, GEOFFREY
AU  - SMITH, BRENDA LYNN
AU  - FALKSON, CARLA ISADORA
AU  - GASMI, JAMAL
AU  - LATEGAN, ANDRIES
AU  - BURILLON, JEAN-PHILIPPE
AU  - HIS, PATRICIA
TI  - Vinorelbine and Cisplatin in Advanced Squamous Cell Carcinoma of the Cervix: The South African Experience
DP  - 2005 May 01
TA  - Anticancer Research
PG  - 2489--2492
VI  - 25
IP  - 3C
4099  - http://ar.iiarjournals.org/content/25/3C/2489.short
4100  - http://ar.iiarjournals.org/content/25/3C/2489.full
SO  - Anticancer Res2005 May 01; 25
AB  - Background: This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma. Patients and Methods: Forty-two patients with advanced cervical cancer were included in the study to receive vinorelbine at 30 mg/m2 on d 1 and d 8 and cisplatin 100 mg/m2 on day 1 every 4 weeks. Results: Thirty-seven patients were evaluable for response and 40 patients for tolerance. Twenty-four patients (64.8%) achieved objective responses. The median duration of response was 17.5 months (range 2.5-57 months), median time to progression was 13.2 months (range 0.4-57 months) and median survival was 20.6 months (range 0.4-55 months). This regimen was well-tolerated; no WHO grade 4 neutropenia was observed, grade 3 nausea and vomiting occured in 50% of patients and grade 2 peripheral neuropathy in 5% of patients. Conclusion: Vinorelbine-cisplatin is an active and well-tolerated regimen in advanced cervical carcinoma.